Brian Gowen

Publications | Abstracts

• Kim, J., Davies, C.J, Gowen, B.B, Yoo, D., Lee, Y., (2024). A CRISPR screen identifies host factors involved in PRRSV replication in a pig macrophage cell line. Proceedings of the 2024 Conference of Research Workers in Animal Diseases

An asterisk (*) at the end of a publication indicates that it has not been peer-reviewed.

Publications | Journal Articles

Academic Journal

• Hicks, P., Westover, J.B, Manzoni, T.B, Petch, R.J, Roper, B., Gowen, B., Bates, P., (2024). Safety, immunogenicity, and efficacy of a recombinant vesicular stomatitis virus vectored vaccine against severe fever with thrombocytopenia syndrome virus and Heartland bandavirus. Vaccines, 12, 1403. doi: https://doi.org/10.3390/vaccines12121403
• Welch, S.R, Bilello, J.P, Carter, K., Delang, L., Dirr, L., Durantel, D., Feng, J.Y, Gowen, B., Herrero, L.J, Janeba, Z., Kleymann, G., Lee, A.A, Meier, C., Moffat, J., Schang, L.M, Shiffer, J.T, Seley-Radtke, K.L, Spengler, J.R, Sheahan, T.P, (2024). Meeting report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research. Antiviral Research, 232, 106037. doi: https://doi.org/10.1016/j.antiviral.2024.106037
• Welch, S.R, Spengler, J.R, Westover, J.B, Bailey, K.W, Davies, K.A, Aida-Ficken, V., Bluemling, G.R, Boardman, K.M, Wasson, S.R, Mao, S., Kuiper, D.L, Hager, M.W, Sandaine, M.T, Andrews, M.K, Krueger, R.E, Steicher, Z.M, Jung, K., Chatterjee, P., Shrivistava-Ranjan, P., Lo, M.K, Coleman-McCray, J.D, Sorvillo, T.E, Genzer, S.C, Sholte, F.E, Kelly, J.A, Jenks, M.H, McMullan, L.K, Albarino, C.G, Montgomery, J.M, Painter, G.R, Natchus, M.G, Kolykhalov, A.A, Gowen, B.B, Spiropoulou, C.F, Flint, M., (2024). Delayed low-dose oral administration of 4'-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Science Translational Medicine, 16, ado7034. doi: DOI: 10.1126/scitranslmed.ado7034
• Watts, D.M, Westover, J.L, Palermo, P.M, Monath, T.P, Bailey, K.W, Bettinger, G.E, Smith, D.R, Morrill, J.C, Pittman, P.R, Orbegozo, J., Gowen, B., (2024). Minimal protective antibody titers elicited in sheep by RVFV MP-12 and arMP-12ΔNSm21/384 vaccine candidates. International Journal of Veterinary Science and Research, 10, 046-062. doi: https://dx.doi.org/10.17352/ijvsr.000149
• Westover, J.B, Bailey, K.W, Wasson, S.R, Boardman, K.M, Lustig, K.H, Amberg, S.M, Gowen, B., (2024). Coadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease. Antiviral Research, 229, 105952. doi: https://doi.org/10.1016/j.antiviral.2024.105952
• Westover, J.B, Jung, K., Alkan, C., Boardman, K.M, Van Wettere, A., Martens, C., Rojas, I., Hicks, P., Thomas, A., Sandaine, M.T, Bluemling, G.R, Mao, S., Kolykhalov, A.A, Natchus, M.G, Bates, P., Painter, G.R, Gowen, B., (2024). Modeling Heartland virus disease in mice and therapeutic intervention with 4'-fluorouridine. Journal of Virology, 98, e00132-24. doi: https://doi.org/10.1128/jvi.00112-24
• Nunberg, J.H, Westover, J.B, York, J., Jung, K., Bailey, K.W, Boardman, K.M, Lee, M., Furnell, R.S, Wasson, S.R, Murray, J.S, Kaundal, R., Thomas, A., Gowen, B., (2024). Restoration of virulence in the attenuated Candid#1 vaccine virus requires reversion at both positions 168 and 427 in the envelope glycoprotein GPC. Journal of Virology, 98, e00112-24. doi: https://doi.org/10.1128/jvi.00112-24
• Chapman, N.S, Hulswit, R.J, Westover, J.L, Stass, R., Paesen, G.C, Binshtein, E., Reidy, J.X, Engdahl, T.B, Handal, L.S, Flores, A., Gowen, B.B, Bowden, T.A, Crowe Jr, J.E, (2023). Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses. Nature Communications, 14, 5650. doi: https://doi.org/10.1038/s41467-023-41171-3
• Spengler, J.R, Carter, K., Delang, L., Durantel, D., Gowen, B., Herrero, L.J, Hurst, B., Janeba, Z., Jordan, R., Luo, D., Meier, C., Moffat, J., Rocha-Pereira, J., Seley-Radtke, K.L, Welch, S.R, Schang, L.M, (2023). Meeting report: 36th International Conference on Antiviral Research in Lyon, France - March 13-17, 2023. Antiviral Research, 217, 105678. doi: https://doi.org/10.1016/j.antiviral.2023.105678
• Westover, J.B, Naik, S., Bailey, K.W, Wandersee, L., Gantla, V.R, Hickerson, B.T, McCormack, K., Henkel, G., Gowen, B., (2022). Severe mammarenaviral disease in guinea pigs effectively treated by an orally bioavailable fusion inhibitor, alone or in combination with favipiravir. Antiviral Research, 208, 105444. doi: https://doi.org/10.1016/j.antiviral.2022.105444
• Watts, D.M, Westover, J.L, Palermo, P.M, Bailey, K.W, Morrill, J.C, Bettinger, G.E, Monath, T.P, Smith, D.R, Peters, C.J, Pittman, P.R, Orbegozo, J., Gowen, B., (2022). Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease. The American Journal of Tropical Medicine and Hygiene, 107:5, 1091-1098. doi: https://doi.org/10.4269/ajtmh.22-0356
• Hickerson, B.T, Daniels-Wells, T.R, Payes, C., Clark, L.E, Candelaria, P.V, Bailey, K.W, Sefing, E.J, Zink, S., Ziegenbein, J., Abraham, J., Helguera, G., Penichet, M.L, Gowen, B., (2022). Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections. Nature Communications, 13, doi: https://doi.org/10.1038/s41467-021-27949-3
• Gowen, B., Naik, S., Westover, J.B, Brown, E.R, Gantla, V.R, Fetsko, A., Dagley, A.L, Blotter, D.J, Anderson, N., McCormack, K., Henkel, G., (2021). Potent inhibition of arenavirus infection by a novel fusion inhibitor. Antiviral Research, 193, 105125. doi: 10.1016/j.antiviral.2021.105125
• Gowen, B., Hickerson, B.T, York, J., Westover, J.B, Sefing, E.J, Bailey, K.W, Wandersee, L., Nunberg, J.H, (2021). Second-generation live-attenuated Candid#1 vaccine virus resists reversion and protects against lethal Junín virus infection in guinea pigs. Journal of Virology, 95, e0039721. doi: 10.1128/JVI.00397-21
• Chapman, N.S, Zhao, H., Kose, N., Westover, J.B, Kalveram, B., Bombardi, R., Rodriguez, J., Sutton, R., Genualdi, J., LaBeaud, A.D, Mutuku, F.M, Pittman, P.R, Freiberg, A.N, Gowen, B.B, Freemont, D.H, Crowe Jr, J.E, (2021). Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. Proceeding of the National Academy of Sciences of the United States of America, 118, e2025642118. doi: 10.1073/pnas.2025642118
• Hawman, D.W, Haddock, E., Meade-White, K., Nardone, G., Feldmann, F., Hanley, P.W, Lovaglio, J., Smith, D.R, Scott, D., Komeno, T., Nakajima, N., Furuta, Y., Gowen, B.B, Feldmann, H., (2020). Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral Research, 181, 104858. doi: 10.1016/j.antiviral.2020.104858
• Monath, T.P, Kortekaas, J., Watts, D.M, Christofferson, R.C, LeaBeaud, A.D, Gowen, B., Peters, C.J, Smith, D.R, Swanepoel, R., Morrill, J.C, Ksiazek, T.G, Pittman, P.R, Bird, B.H, Bettinger, G., (2020). Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. Vaccine X, 5, e100060. doi: 10.1016/j.jvacx.2020.100060
• Hickerson, B.T, Sefing, E.J, Bailey, K.W, Van Wettere, A.J, Penichet, M.L, Gowen, B., (2020). Type I interferon underlies severe disease associated with Junín virus infection in mice. eLife, 9, e55325. doi: 10.7554/eLife.55352
• Hickerson, B.T, Westover, J.B, Wang, Z., Lee, Y., Gowen, B.B, (2019). Guinea pig transferrin receptor 1 mediates cellular entry of Junin virus and other pathogenic New World arenaviruses. Journal of Virology (J Virol), 94:4, e01278-19. doi: 10.1128/JVI.01278-19
• Tramontano, E., Tarbet, B., Spengler, J.R, Seley-Radtke, K., Meier, C., Jordan, R., Janeba, Z., Gowen, B., Gentry, B., Este, J.A, Bray, M., Andrei, G., Schang, L.M, I., (2019). Meeting report: 32nd International Conference on Antiviral Research. Antiviral Research, 169, 104550. doi: 10.1016/j.antiviral.2019.104550
• Smee, D., Jung, K., Westover, J.B, Gowen, B., (2018). 2′-Fluoro-2′-deoxycytidine is a broad-spectrum inhibitor of bunyaviruses in vitro and in phleboviral disease mouse models. Antiviral Res
• Madu, I.G, Files, M., Gharaibeh, D.M, Moore, A.L, Jung, K., Gowen, B., Dai, D., Jones, K.F, Tyavanagimatt, S.R, Burgeson, J.R, Korth, M.J, Bedard, K.M, Iadonato, S.P, Amberg, S.M, (2018). Characterization of a potent arenavirus antiviral identifies correlation between inhibitor sensitivity and virulence.. PLoS Pathog
• Hawman, D.W, Haddock, E., Meade-White, K., Williamson, B., Hanley, P.W, Rosenke, K., Komeno, T., Furuta, Y., Gowen, B., Feldmann, H., (2018). Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral Res
• Rosenke, K., Feldmann, H., Westover, J.B, Hanley, P.W, Martellaro, C., Feldmann, F., Saturday, G., Lovaglio, J., Scott, D.P, Furuta, Y., Komeno, T., Gowen, B., Safronetz, D., (2018). Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis
• Westover, J.B, Mathis, A., Taylor, R., Wandersee, L., Bailey, K.W, Sefing, E.J, Hickerson, B.T, Sheridan, W.P, Gowen, B., (2018). Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral Res
• Hickerson, B.T, Westover, J.B, Jung, K., Komeno, T., Furuta, Y., Gowen, B., (2018). Effective treatment of experimental lymphocytic choriomeningitis virus infection: consideration of favipiravir for use with infected organ transplant recipients. J Infect Dis
• Westover, J.B, Rigas, j., Van Wettere, A., Li , R., Hickerson, B.T, Jung, K.H, Miao, J., Reynolds, E.S, Conrad, B.L, Nielson, S., Furuta, Y., Thangamani, S., Wang, Z., Gowen, B., (2017). Heartland virus infection in hamsters deficient in type I interferon signaling: Protracted disease course ameliorated by favipiravir. Virology, 511, 175-183.
• Gowen, B., Westover, J.B, Sefing, E.J, Van Wettere, A., Bailey, K.W, Wandersee, L., Komeno, T., Furuta, Y., (2017). Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral Research
• Gowen, B., Hickerson, B.T, (2017). Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies. Journal of Microbiology
• Gowen, B., Westover, J.B, Miao, J., Van Wettere, A., Rigas, J., Hickerson, B.T, Jung, K.H, Li, R., Conrad, B.L, Nielson, S., Furuta, Y., Wang, Z., (2017). Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: Importance of STAT2 in preventing disease and effective treatment with favipiravir. Journal of Virology
• Westover, J.B, Sefing, E.J, Bailey, K.W, Van Wettere, A., Jung, K., Dagley, A., Wandersee, L., Downs, B., Smee, D., Furuta, Y., Bray, M., Gowen, B., (2016). Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Research
• Safronetz, D., Rosenke, K., Westover, J.B, Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J., Saturday, G., Komeno, T., Geisbert, T.W, Feldmann, H., Gowen, B., (2015). The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep, 5, 14775.
• Gowen, B., Sefing, E.J, Westover, J.B, Smee, D., Hagloch, J.H, Furuta, Y., Hall, J.O, (2015). Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res , 121, 132–137.
• Gowen, B., Westover, J.B, Sefing, E.J, Bailey, K.W, Nishiyama, S., Wandersee, L., Scharton, D., Jung, K.H, Ikegami, T., (2015). MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters. Front Microbiol, 6, 651.
• Falcinelli, S., Gowen, B., Trost, B., Napper, S., Kusalik, A., Johnson, R.F, Safronetz, D., Prescott, J., Kindrachuck, J., (2015). Characterization of the host response to Pichinde virus infection in the Syrian golden hamster by species-specific kinome analysis. Mol Cell Proteomics, 14, 646-57.
• Scharton, D., Van Wettere, A., Bailey, K.W, Vest, Z., Westover, J.B, Siddharthan, V., Gowen, B., (2015). Rift Valley Fever Virus Infection in Golden Syrian Hamsters. PLoS ONE, 10:1, e0116722.
• Smith, D.R, Holbrook, M.R, Gowen, B., (2014). Animal Models of Viral Hemorrhagic Fever. Antiviral Research, 112C, 59-79.
• Dagley, A., Ennis, J., Turner, J.D, Rood, K., Van Wettere, A., Gowen, B., Julander, J., (2014). Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201). Antiviral Research, 108, 1-9. doi: 10.1016/j.antiviral.2014.05.004
• Scharton, D., Bailey, K.W, Vest, Z., Westover, J.B, Kumaki, Y., Skirpstunas, R., Furuta, Y., Gowen, B., (2014). Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Research, 104, 84-92.
• Gowen, B., Ennis, J., Bailey, K., Vest, Z., Scharton, D., Sefing, E.J, Turner, J., (2014). Single-dose intranasal treatment with DEF201 (adenovirus vectored consensus interferon) prevents lethal disease due to Rift Valley fever virus challenge. Viruses, 108, 1-9.
• Gowen, B., Jung, K., Sefing, E.J, Wong, M., Westover, J.B, Smee, D., (2014). Activity of a phenolic dibenzylsulfide against New World arenavirus infections. Antiviral Chemistry & Chemotherapy, 23:4, 151-159.
• Gowen, B., Juelich, T.L, Sefing, E.J, Brasel, T., Smith, J.K, Zhang, L., Tigabu, B., Hill, T.E, Yun, T., Pietzsch, C., Furuta, Y., Freiberg, A.N, (2013). Favipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever. PLoS Negl. Trop. Dis., 7:12, e2614.
• Furuta, Y., Gowen, B., Takahashi, K., Shiraki, K., Smee, D., Barnard, D., (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research, 100:2, 446-454.
• Safronetz, D., Falzarano, D., Scott, D.P, Furuta, Y., Feldmann, H., Gowen, B., (2013). Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimocrobial Agents & Chemotherapy, 57:10, 4673-80.
• Sefing, E.J, Wong, M., Larson, D.P, Hurst, B.L, Van Wettere, A., Schneller, S.W, Gowen, B., (2013). Vascular leak ensues a vigorous proinflammatory cytokine response to Tacaribe arenavirus infection in AG129 mice. Virology Journal, 10, 221.
• Gowen, B., Bailey, K.W, Scharton, D., Vest, Z., Westover, J.B, Skirpstunas, R., Ikegami, T., (2013). Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Antiviral Research, 98:2, 135-143.
• Gowen, B., Ennis, J., Sefing, E.J, Wong, M., Jung, K., Turner, J., (2012). Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201). Antimocrobial Agents & Chemotherapy, 56:8, 4168-74.
• Gowen, B., Bray, M., (2011). Progress in the experimental therapy of severe arenaviral infections. Future Microbiol, 6, 1429-41.
• Gowen, B., Ennis, J., Andrew, R., Sefing, E.J, Wong, M., Turner, J., (2011). Use of recombinant adenovirus vectored consensus IFN-α to avert severe arenavirus infection. PLoS One, 6:10, e26072.
• Mendenhall, M., Russell, A., Smee, D., Hall, J.O, Skirpstunas, R., Furuta, Y., Gowen, B., (2011). Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl. Trop. Dis., 5:10, e1342.
• Buys, K.K, Jung, K., Smee, D., Furuta, Y., Gowen, B., (2011). Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir. Chem. Chemother., 21:5, 193-200.
• Mendenhall, M., Russell, A., Juelich, T., Messina, E.L, Smee, D., Freiberg, A.N, Holbrook, M.R, Furuta, Y., de la Torre, J.C, Nunberg, J.H, Gowen, B., (2011). T-705 (Favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob. Agents Chemother., 55:2, 782-787.
• Gowen, B., Julander, J., London, N.R, Wong, M.H, Larson, D., Morrey, J.D, Li, D.Y, Bray, M., (2010). Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J., 7, 240.
• Gowen, B., Julander, J., London, N.R, Wong, M.H, Larson, D., Morrey, J.D, Li, D.Y, Bray, M., (2010). Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virol. J., 7:240, 1-13.
• Gowen, B., Wong, M.H, Larson, D., Ye, W., Jung, K.H, Sefing, E.J, Skirpstunas, R., Smee, D., Morrey, J.D, Schneller, S.W, (2010). Development of a new Tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS ONE, 5:9, pii: e12760.
• Gowen, B., Wong, M., Jung, K., Smee, D., Morrey, J.D, Furuta, Y., (2010). Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res., 86:2, 121-127.
• Mendenhall, M., Wong, M.H, Skirpstunas, R., Morrey, J.D, Gowen, B., (2009). Punta Toro virus (Bunyaviridae, Phlebovirus) infection in mice: strain differences in pathogenesis and host interferon response.. Virology, 395, 143-51.
• Duran, N., Gowen, B., Costa, F.T, Justo, G.Z, Brocchi, M., Nunes, O.S, Nunes, I.S, (2009). A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus.. Antiviral Res, 83:2, 143-7.
• Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D., Barnard, D., Gowen, B., Julander, J., Morrey, J.D, (2009). T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res, 82:3, 95-102.
• Gowen, B., Fairman, J., Dow, S.W, Troyer , R., Wong, M.H, Jung, K.H, Melby, P.C, Morrey, J.D, (2009). Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: Importance of liposomal delivery and CpG motifs.. Antiviral Res, 81:1, 37-46.
• Smee, D., Gowen, B., Wandersee, M.K, Wong, M., Skirpstunas, R., Baldwin, T.J, Hoopes, J.D, Sidwell, R.W, (2008). Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. International Journal of Antimicrobial Agents, 31, 352-359.
• Gowen, B., Smee, D., Wong, M., Hall, J.O, Jung, K., Bailey, K.W, Stevens, J.R, Furuta, Y., Morrey, J.D, (2008). Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE, 3:11, e3725.
• Gowen, B., Judge, J.W, Wong, M.H, Jung, K.H, Aylsworth, C.F, Melby, P.C, Rosenberg, B., Morrey, J.D, (2008). Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen.. Int. Immunopharmacol., 8, 1089-94.
• Subramanian, G.M, Moore, P.A, Gowen, B., Olsen, A.L, Barnard, D., Paragas, J., Hogan, R.J, Sidwell, R.W, (2008). Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy, 54:3, 176-180.
• Holbrook, M.R, Gowen, B., (2008). Animal models of highly pathogenic RNA viral infections: Encephalitis viruses. Antiviral Res., 78, 69-78.
• Gowen, B., Holbrook, M.R, (2008). Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antiviral Res., 78, 79-90.
• Smee, D., Gowen, B., Wandersee, M.K, Wong, M., Skirpstunas, R.T, Baldwin, T.J, Hoopes, J.D, Sidwell, R.W, (2008). Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes, and effects of cidofovir treatment. Int. J. Antimicrob. Agents, 31:4, 352-359.
• Gowen, B., Wong, M.H, Jung, K.H, Blatt, L.M, Sidwell, R.W, (2008). Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with Interferon Alfacon-1.. Antiviral Res., 77, 215-24.
• Ma, X., Liu, Y., Gowen, B., Graviss, E.A, Clark, A.G, Musser, J.M, (2007). Full-exon sequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease.. PLoS ONE, 2, e1318.
• Selvam, P., Vijayalakshimi, P., Smee, D., Gowen, B., Julander, J., Day, C.W, Barnard, D., (2007). Novel 3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of antiviral activities against respiratory and biodefense viruses.. Antiviral Chemistry and Chemotherapy/International Medical Press, 18:5, 301-5.
• Gowen, B., Wong, M.H, Jung, K.H, Sanders, A.B, Mendenhall, M., Bailey, K.W, Furuta, Y., Sidwell, R.W, (2007). In vitro and in vivo activity of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother., 51, 3168-76.
• Selvam, P., Vigayalakshimi, B., Smee, D.F, Gowen, B., Julander, J.G, Day, C.W, Barnard, D.L, (2007). Novel-3-sulphonamido-quinazolin-4(3H)-one derivatives: microwave-assisted synthesis and evaluation of anti-viral activities against respiratory and biodefense viruses. Antivir. Chem. Chemother., 18, 301-5.
• Gowen, B., Wong, M.H, Jung, K.H, Mitchell, W.M, Sanders, A.B, Alexopoulou, L., Flavell, R.A, Sidwell, R.W, (2007). TLR3 is essential for the induction of protective immunity against Punta Toro virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not poly(I:C): Differential recognition of synthetic dsRNA molecules. J. Immunol., 178, 5200-8.
• Gowen, B., Hoopes, J.D, Wong, M.H, Jung, K.H, Isakson, K.C, Alexopoulou, L., Flavell, R.A, Sidwell, R.W, (2006). TLR3 deletion limits mortality and disease severity due to phlebovirus infection. J. Immunol., 177, 6301-7.
• Gowen, B., Smee, D.F, Wong, M.H, Pace, A.M, Jung, K.H, Bailey, K.W, Blatt, L.M, Sidwell, R.W, (2006). Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir. Chem. Chemother., 17, 175-83.
• Gowen, B., Smee, D.F, Wong, M.H, Judge, J.W, Jung, K.H, Bailey, K.W, Pace, A.M, Rosenberg, B., Sidwell, R.W, (2006). Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob. Agents Chemother., 50, 2023-9.
• Gowen, B., Fairman, J., Smee, D.F, Wong, M.H, Jung, K.H, Pace, A.M, Heiner, M.L, Bailey, K.W, Dow, S.W, Sidwell, R.W, (2006). Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res., 69, 165-72.
• Gowen, B., Barnard, D.L, Smee, D.F, Wong, M.H, Pace, A.M, Jung, K.H, Winslow, S.G, Bailey, K.W, Blatt, L.M, Sidwell, R.W, (2005). Interferon alfacon-1 protects hamsters from lethal Pichinde virus infection. Antimicrob. Agents Chemother., 49, 2378-86.
• Sebbane, F., Gardner, D., Long, D., Gowen, B., Hinnebusch, B.J, (2005). Kinetics of disease progression and host response in a rat model of bubonic plague. Am. J. Pathol., 166, 1427-39.
• Graham, M.R, Virtaneva, K., Porcella, S.F, Barry, W.T, Gowen, B., Johnson, C.A, Wright, F.A, Musser, J.M, (2005). Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am. J. Pathol., 166, 455-65.
• Rebeil, R., Ernst, R.K, Gowen, B., Miller, S.I, Hinnebusch, B.J, (2004). Variation in lipid A structure in the pathogenic yersiniae. Mol. Microbiol., 52, 1363-73.
• Hoe, N.P, Ireland, R.M, Deleo, F.R, Gowen, B., Dorward, D.W, Voyich, J.M, Liu, M., Burns, Jr., E.H, Culnan, D.M, Bretscher, A., Musser, J.M, (2002). Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc. Nat. Acad. Sci. USA, 99, 7646-51.
• Gowen, B., Borg, T.K, Ghaffar, A., Mayer, E.P, (2001). The collagenous domain of class A scavenger receptors is involved in macrophage adhesion to collagens. J. Leukoc. Biol., 69, 575-82.
• Gowen, B., Borg, T.K, Ghaffer, A., Mayer, E.P, (2000). Selective adhesion of macrophages to denatured forms of type I collagen is mediated by scavenger receptors. Matrix Biol., 19, 61-71.

An asterisk (*) at the end of a publication indicates that it has not been peer-reviewed.

Publications | Technical Reports

Research Reports

• Morrey, J.D, Barnard, D., Smee, D., Gowen, B., (2009). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2009). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Morrey, J.D, Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2009). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2009). Semi-Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Morrey, J.D, Barnard, D., Smee, D., Gowen, B., (2008). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Morrey, J.D, Barnard, D., Smee, D., Gowen, B., (2008). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2008). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Morrey, J.D, Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2008). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2008). Semi-Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Morrey, J.D, Barnard, D., Smee, D., Gowen, B., (2007). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2007). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Morrey, J.D, Barnard, D., Smee, D., Gowen, B., (2007). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Smee, D., Barnard, D., Morrey, J.D, Gowen, B., Julander, J., (2007). Semi-Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2006). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., Julander, J., (2006). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., Julander, J., (2006). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2006). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2005). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2005). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2005). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2004). Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2004). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2004). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2004). Semi-Annual Report NO1-AI-15435, NIAID, NIH. Animals Models of Human Experimental Viral Infections for Evaluation of Experimental Therapies.
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2003). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2003). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2002). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2002). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2001). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2001). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2000). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (2000). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (1999). Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .
• Sidwell, R., Barnard, D., Morrey, J.D, Smee, D., Gowen, B., (1999). Semi Annual Report NO1-AI-85348, NIAID, NIH. In vitro antiviral screen for respiratory viruses. .

An asterisk (*) at the end of a publication indicates that it has not been peer-reviewed.

Publications | Other

An asterisk (*) at the end of a publication indicates that it has not been peer-reviewed.